323 results on '"Muro K"'
Search Results
2. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
4. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study
5. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)
6. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
7. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
8. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
9. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
10. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
11. O7-4 A phase 1 study of zanidatamab monotherapy in Japanese patients with metastatic or unresectable HER2-expressing cancers.
12. 1259TiP Investigator-initiated phase II study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability—high advanced gastric or esophagogastric junction cancer (NO LIMIT, WJOG13320G/CA209-7W7)
13. 1244P Prognostic impact of myeloid subsets in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)
14. 1224P Final analysis of clinical outcomes in the DELIVER trial: Observational study of nivolumab treatment in advanced gastric cancer (JACCRO GC-08)
15. 389P Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)
16. 1217P Profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)
17. 388P Early tumor shrinkage (ETS) and depth of response (DpR) analyses in metastatic colorectal cancer (mCRC) treated with first-line mFOLFOX6 plus panitumumab (PAN) or bevacizumab (BEV): Results from the phase III PARADIGM trial
18. 1241P Phase Ib study of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors: Tolerability results and antitumor activity in esophageal carcinoma
19. 599TiP PRABITAS study: A pragmatic, randomized, phase III trial of biweekly vs. conventional use of trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer
20. 522P Impact of age and single heterozygous UGT1A1 on the safety and efficacy of first-line FOLFIRI or FOLFOXIRI in combination with ramucirumab (RAM) for metastatic colorectal cancer (mCRC): Subgroup analyses of WJOG9216G (RECAST)
21. 523P A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)
22. 518MO Update analysis of the randomized phase II study comparing FOLFIRI plus ramucirumab (RAM) versus FOLFOXIRI plus RAM as first-line treatment for patients with metastatic colorectal cancer: WJOG9216G (RECAST)
23. P-61 Impacts of salvage chemotherapy after nivolumab therapy (NIVO): A REVIVE substudy
24. P-134 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including multiple gastroesophageal cancer cohorts
25. P-99 A multicenter phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases: WJOG10517G
26. P-95 Bevacizumab, irinotecan and biweekly trifluridine/tipiracil for pretreated metastatic colorectal cancer: MODURATE, a phase Ib study
27. P-57 An observational/translational study of BRAF inhibitor combination therapy for BRAF-mutant metastatic colorectal cancer including biomarker research: BEETS trial (JACCRO CC-18)
28. LBA O-10 First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results
29. P-80 A multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab and FOLFOXIRI plus bevacizumab as the first-line treatment for metastatic colorectal cancer: A safety analysis of the QUATTRO-II study
30. Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel
31. MO25-3 Safety and pharmacokinetics of tusamitamab ravtansine dosing Q3W in Japanese patients with advanced solid tumors.
32. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)
33. 1418P Chronological improvement in the survival of advanced gastric cancer patients in the past 15 years
34. PD-014 Final survival results and onset of neutropenia as an indicator of therapeutic effect in phase 2 of TAS-102 vs placebo with metastatic colorectal cancer (J003-10040030)
35. O-007 Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
36. SO-17 The global POLAR program: Top-line results of placebo-controlled studies of calmangafodipir on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy
37. SO-19 A multicenter phase Ⅱ trial of trifluridine/tipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody therapy: The WJOG8916G trial
38. O-13 Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08)
39. P-155 A phase I study of FLOT as first-line therapy for Japanese patients with advanced gastric cancer including patients with or without severe peritoneal metastasis
40. O-6 Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial
41. P-63 MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer
42. P-95 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers
43. P-28 Exploratory analysis of patients with gastric/GEJ adenocarcinoma with or without liver metastasis from the phase 3 RAINBOW study
44. LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
45. 615P The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
46. 1532P Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy
47. 1513MO A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)
48. P-199 Comparison of treatment outcomes of regorafenib for patients with metastatic colorectal cancer by era: A propensity-score matched analysis
49. P-149 QUATTRO-II: A multicenter randomized trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Efficacy and safety analysis
50. P-80 Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.